At a glance
- Originator Novartis
- Class Analgesics; Anti-inflammatories; Antipyretics; Antirheumatics; Piperazines
- Mechanism of Action Interleukin 1 alpha inhibitors; Interleukin 1 beta inhibitors; Interleukin 6 inhibitors; Tumour necrosis factor inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- Discontinued Rheumatic disorders
Most Recent Events
- 02 Jun 1995 Discontinued-Preclinical for Rheumatic disorders in Switzerland (Unknown route)